Semustine

Semustine
Clinical data
ATC code
Identifiers
IUPAC name
  • N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.162.271
Edit this at Wikidata
Chemical and physical data
FormulaC10H18ClN3O2
Molar mass247.72 g·mol−1
3D model (JSmol)
SMILES
  • CC1CCC(CC1)NC(=O)N(CCCl)N=O
InChI
  • InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15) ☒N
  • Key:FVLVBPDQNARYJU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Semustine is a drug used in chemotherapy.[1] It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.[2]

References

  1. ↑ Woolley PV, Nauta R, Smith FP, Lindblad AS, Petrelli N, Herrera L, et al. (Gastrointestinal Tumor Study Group) (April 1992). "Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group". Journal of Clinical Oncology. 10 (4): 549–57. doi:10.1200/jco.1992.10.4.549. PMID 1548520.
  2. ↑ "Known and Probable Human Carcinogens". American Cancer Society.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.